BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 19238013)

  • 1. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
    Lapteva N; Aldrich M; Weksberg D; Rollins L; Goltsova T; Chen SY; Huang XF
    J Immunother; 2009; 32(2):145-56. PubMed ID: 19238013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.
    Lapteva N; Aldrich M; Rollins L; Ren W; Goltsova T; Chen SY; Huang XF
    Mol Ther; 2009 Sep; 17(9):1626-36. PubMed ID: 19532135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy.
    Kim IW; Yoon AR; Hong J; Kasala D; Yun CO
    Front Immunol; 2024; 15():1355566. PubMed ID: 38835775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
    Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
    J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
    Ye JF; Qi WX; Liu MY; Li Y
    Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
    Choi IK; Li Y; Oh E; Kim J; Yun CO
    PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
    Ahn HM; Hong J; Yun CO
    Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
    Oh E; Choi IK; Hong J; Yun CO
    Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.
    Zhang SN; Choi IK; Huang JH; Yoo JY; Choi KJ; Yun CO
    Mol Ther; 2011 Aug; 19(8):1558-68. PubMed ID: 21468000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.